MEDA Angels
Status
ACTIVE
Global HQ
Arlington, United States
Countries of investment
- USA
Investment stages
- Pre-Seed
- Seed
- Series A
- Series B
Industries
- Health Tech
About
MEDA Angels is a distinguished healthcare angel investor group, established by a community of physicians and scientists committed to advancing the field of medicine. The organization specializes in investing in pioneering startups within the realms of medical devices, digital health, wellness, and repurposed therapeutics. With a focus on innovation, MEDA Angels not only provides crucial funding but also offers strategic guidance and mentorship to its portfolio companies, fostering their growth and success in a competitive landscape. Through a collaborative approach, MEDA Angels aims to drive transformative changes in healthcare, improving patient outcomes and enhancing the quality of life.
MEDA Angels is a distinguished healthcare angel investor group, established by a community of physicians and scientists committed to advancing the field of medicine. The organization specializes in investing in pioneering startups within the realms of medical devices, digital health, wellness, and repurposed therapeutics. With a focus on innovation, MEDA Angels not only provides crucial funding but also offers strategic guidance and mentorship to its portfolio companies, fostering their growth and success in a competitive landscape. Through a collaborative approach, MEDA Angels aims to drive transformative changes in healthcare, improving patient outcomes and enhancing the quality of life.
Investment Thesis
MEDA Angels is founded by physicians and scientists, focusing on investing in healthcare for all. They leverage their extensive networks and experience in the healthcare and investor ecosystem to support their portfolio companies actively.
Manager's Experience
With extensive expertise in the private equity industry, the fund manager has successfully navigated a diverse array of sectors, particularly in technology and healthcare. Having executed over 30 deals across North America and Europe, they emphasize a data-driven, thematic investment approach that targets early to growth-stage companies. Their strategic style has led to notable exits, showcasing a keen ability to identify and capitalize on high-potential opportunities. This depth of experience underlines a commitment to fostering innovation and driving value creation in portfolio companies.